According to a Study Published in the New England Journal of Medicine, Combined Estrogen-Progestin Birth Control Methods, Such as NuvaRing, Yaz or Yasmin, May Double a Woman’s Risk of Stroke and Heart Attack Compared to Other Hormonal Contraceptives.
Melville, NY (PRWEB) June 15, 2012
Attorneys Andres Alonso and David Krangle, founding partners of Alonso Krangle LLP, a leading law firm focused on fighting for the rights of serious personal injury victims due to harmful drugs and defective medical devices, is alerting young women who use combined hormonal birth control methods, including the NuvaRing vaginal ring, as well as Yaz and Yasmin birth control pills, that they may face a significantly higher risk of experiencing a heart attack or stroke compared to users of other forms of hormonal birth control. A study published in the New England Journal of Medicine on June 14 suggests that these and other forms of birth control that contain a combination of estrogen and progestin can double a woman’s risk of having a heart attack or stroke. New England Journal of Medicine Article: Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception
Alonso Krangle is currently offering FREE NuvaRing lawsuit consultations or FREE Yaz lawsuit consultations to users of NuvaRing, Yaz and Yasmin who may have suffered a serious side effect associated with the use of these drugs, including:
- Venous Thromboembolism ( Blood Clots )
- Deep vein thrombosis
- Pulmonary embolism
- Heart attacks
The New England Journal of Medicine study, conducted by scientists in Denmark, analyzed 15 years of observational data from more than 1.6 million women aged 15 to 49. Women taking low-dose estrogen birth control pills combined with progestins suffered heart attacks and strokes between 1.5 and 2 times more often than women not using hormonal contraception. The risks were as much 2.5 to 3 times higher among users of combined hormonal device, including vaginal rings, compared to non-users. The highest risks were seen in women over 45, or those who had high blood pressure.
Introduced in 2001, NuvaRing is a hormonal vaginal ring that releases a combination of etonogestrel, a synthetic generation progestin, and the estrogen, ethinyl estradiol. Last October, results from a study funded by the U.S. Food & Drug Administration (FDA) involving data on 800,000 American women using some form birth control between 2001 and 2008 revealed using NuvaRing increased the risk of blood clots, including deep vein thrombosis and pulmonary embolism, by 56% in comparison to older birth control pills. A second study, published on May 10, 2012 in the online edition of the British Medical Journal, found that NuvaRing users had a 6.5 times higher risk of experiencing a serious blood clot compared to women who did not use any form of hormonal birth control. The likelihood of experiencing a dangerous blood clot was 90% higher among users of the vaginal ring than it was for women taking combined oral contraceptives containing levonorgestrel. FDA.gov: Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints
Hundreds of NuvaRing lawsuits alleging the device caused serious side effects, including blood clots, deep vein thrombosis, pulmonary embolism, heart attacks, strokes and wrongful death are currently pending in a multidistrict litigation in the U.S. District Court, Eastern District of Missouri (MDL No. 1964). Additional NuvaRing lawsuits are pending in a Mass Tort proceeding in the Bergen County Superior Court of New Jersey (Docket No. BER-L-3081-09).
About Yaz and Yasmin
Yaz and Yasmin both contain ethinyl estradiol, along with a synthetic progestin called drospirenone. The FDA’s study of hormonal contraceptives that was released last October suggested an approximately 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing pills compared to users of other hormonal contraceptives. In a Drug Safety Communication issued on April 10, 2012, the FDA said it was requiring that the labels for drospirenone birth control be updated to warn that these contraceptives may be linked to a higher risk of blood clots. FDA Drug Safety Communication: Update on the possible increased risk of blood clots with birth control pills containing drospirenone
More than 10,000 personal injury lawsuits that allege Yaz and Yasmin caused heart attacks, strokes, blood clots and other serious injuries are currently pending in the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100) in the U.S. District Court for the Southern District of Illinois. Andres Alonso is serving as a member of the Plaintiffs’ Steering Committee in that litigation.
Alonso Krangle LLP continues to offer free lawsuit evaluations to users of Yaz, Yasmin and NuvaRing who have suffered serious injuries, including heart attacks, strokes and blood clots. To discuss a potential claim with one of the defective drug lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website FightForVictims.com
About Alonso Krangle LLP
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A leading law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and plans to open additional locations in New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com